Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1623 1631 1632 1633 1634 1658 1674 1699
This examiner grants 73% of resolved cases
Masudur Rahman is an examiner in Tech Center 1600 and Art Unit 1600. The examiner has 128 resolved cases. The allowance rate is 72.7%. This 72.7% rate indicates the frequency of patent grants among the 128 resolved cases. Practitioners can use this 72.7% figure to assess the likelihood of success when prosecuting applications before this examiner.
The interview lift is 31.7%. This 31.7% lift indicates the change in the likelihood of receiving an allowance after conducting an interview. The 31.7% lift suggests that interviews are associated with an increase in the probability of a grant. The median days to allowance is 1422. This 1422 day period provides a timeframe for the duration of the prosecution process from filing to a grant. The 1422 days represent the median point for reaching a resolution in Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18561929 | METHODS AND MATERIALS FOR TREATING PROTEINOPATHIES | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18271294 | DRIED CELL SECRETOME-BASED THERAPEUTIC AGENT FOR OSTEOARTHRITIS TREATMENT | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18838764 | MICROORGANISMS WITH REDUCED COMPETENCE | Non-Final OA | Evonik Operations GmbH |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | Final Rejection | NOVARTIS AG |
| 18015791 | EXPOSURE UNIT, OBSERVATION DEVICE, AND EXPOSURE METHOD | Final Rejection | HAMAMATSU PHOTONICS K.K. |
| 17616522 | METHODS OF MAKING AND USING LIVER CELLS | Final Rejection | University Health Network |
| 18420721 | CELLULAR COMPOSITIONS FOR TREATING BACK PAIN | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18696866 | HUMAN HEPATOCYTE CULTURE MEDIUM AND CONDITIONED MEDIUM OF IN VITRO CULTURED HUMAN HEPATOCYTES AND USES THEREOF | Non-Final OA | PhoenixBio Co., Ltd. |
| 18366306 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | Non-Final OA | Elanco Animal Health GmbH |
| 18718051 | Purification Method of Viral Vectors | Non-Final OA | Oxford Biomedica (UK) Limited |
| 18701572 | Method for the generation of genetically modified NK cells | Non-Final OA | MILTENYI BIOTEC B.V. & CO. KG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy